Alumis Inc. Prices Upsized Public Offering of 17.65 Million Shares, Raising Approximately $300 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy ALMS?
Source: Globenewswire
- Upsized Offering: Alumis Inc. announced the pricing of an upsized public offering of 17.65 million shares at $17.00 per share, expected to raise approximately $300 million, significantly enhancing the company's research capabilities in immune-mediated diseases.
- Underwriter Selection: The offering is managed by Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities, ensuring professionalism and market credibility, which boosts investor confidence in the offering.
- Additional Share Option: Alumis granted underwriters a 30-day option to purchase up to an additional 2.65 million shares at the public offering price, enhancing market liquidity and providing the company with additional financing flexibility.
- Regulatory Compliance: The public offering is conducted under an SEC-approved S-3 shelf registration statement, ensuring compliance and laying the groundwork for future financing activities, thereby enhancing the company's credibility in capital markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMS
Wall Street analysts forecast ALMS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.800
Low
32.00
Averages
37.67
High
50.00
Current: 26.800
Low
32.00
Averages
37.67
High
50.00
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BML Capital Management Fully Exits Alumis Stake
- Exit Transaction: On February 2, BML Capital Management disclosed in an SEC filing that it completely liquidated its 1,210,415 shares of Alumis for approximately $4.83 million, resulting in a significant reduction in its quarter-end position value, highlighting its risk management strategy regarding the stock.
- Market Performance: As of February 2, Alumis shares were priced at $26.42, reflecting a staggering 255.1% increase over the past year, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market confidence in its clinical-stage therapies.
- Company Overview: Alumis focuses on developing clinical-stage therapies for autoimmune and neuroinflammatory disorders, particularly TYK2 inhibitors, and despite reporting a net loss of $245.15 million, its R&D pipeline suggests substantial market potential.
- Investor Insight: BML's exit serves as a reminder that disciplined portfolio decisions can be impacted by fast-moving market catalysts, as Alumis's subsequent financing activities alleviated capital risk and reversed market sentiment, illustrating the dynamic nature of the biotech sector.
See More
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
- Market Surge: U.S. stocks rose significantly on Monday, with the Dow Jones index gaining over 350 points, indicating strong investor confidence and potentially attracting more capital into the market.
- Peakstone Realty Trust Price Surge: Shares of Peakstone Realty Trust soared 32.5% to $20.70 on Friday, reflecting positive market sentiment regarding the company's future prospects and the anticipated benefits of the acquisition.
- Acquisition Announcement: Brookfield announced plans to acquire Peakstone Realty Trust in a $1.2 billion all-cash deal, which not only enhances Brookfield's asset portfolio but also signals its strategic intent to expand further in the real estate sector.
- Positive Market Reaction: Following the acquisition news, Peakstone Realty Trust's stock price surged, indicating strong investor confidence in the deal and potentially attracting additional investment into the company.
See More
Analysts Bullish on Century Communities, Target Price Set at $92
- Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
- Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
- Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
- Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.
See More
Alumis Director Srinivas Akkaraju Purchases 588,235 Shares for ~$10 Million
- Large Transaction: On January 9, 2026, Srinivas Akkaraju purchased 588,235 shares of Alumis at $17 per share for a total of approximately $10 million, marking one of the largest trades in his history and exceeding the historical median trade size by nearly 47%.
- Increased Indirect Holdings: Following this transaction, Akkaraju's indirect holdings rose to 1,853,488 shares, reflecting his confidence in Alumis's future growth, particularly as the company's stock has surged over 400% in the past year.
- Market Price Comparison: The acquisition price was below the market open of $18.50 and close of $19.56 on January 9, 2026, indicating a favorable entry point for Akkaraju ahead of subsequent price increases, suggesting expectations of further appreciation.
- Clinical Trial Success: Alumis recently reported that 65% of patients in two Phase 3 trials with envudeucitinib achieved a 90% or better improvement in their psoriasis area and severity index (PASI) scores, indicating superior efficacy compared to Amgen's Otezla, further boosting market confidence in its products.
See More
Alumis (NASDAQ:ALMS) Acquires 588,235 Shares for $10 Million
- Share Acquisition: On January 9, 2026, Alumis Director Srinivas Akkaraju purchased 588,235 shares at $17 each for a total of approximately $10 million, demonstrating strong confidence in the company's future growth prospects.
- Holding Proportion Change: This transaction increased Akkaraju's indirect holdings to 46.49%, with no direct holdings reported post-transaction, indicating a strategic investment approach through the Samsara Opportunity Fund, L.P.
- Stock Performance: Alumis's stock has appreciated by 206.29% over the past year and surged over 400% in the last three months, reflecting strong market recognition and potential for its biotechnology products.
- Clinical Trial Success: Recent Phase 3 trial results from Alumis revealed that 65% of patients using envudeucitinib achieved a 90% or better improvement in their Psoriasis Area and Severity Index (PASI) scores, indicating its potential to outperform competitor Otezla in treating psoriasis.
See More
Activist Investors Target Staar Surgical, Alumis, and Other Stocks
Increased Investments: There has been a notable rise in holdings across various sectors, indicating a growing confidence among investors.
Market Trends: The increase in holdings reflects broader market trends, suggesting potential growth opportunities in the near future.
See More
BML Capital Management Fully Exits Alumis Stake
- Exit Transaction: On February 2, BML Capital Management disclosed in an SEC filing that it completely liquidated its 1,210,415 shares of Alumis for approximately $4.83 million, resulting in a significant reduction in its quarter-end position value, highlighting its risk management strategy regarding the stock.
- Market Performance: As of February 2, Alumis shares were priced at $26.42, reflecting a staggering 255.1% increase over the past year, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market confidence in its clinical-stage therapies.
- Company Overview: Alumis focuses on developing clinical-stage therapies for autoimmune and neuroinflammatory disorders, particularly TYK2 inhibitors, and despite reporting a net loss of $245.15 million, its R&D pipeline suggests substantial market potential.
- Investor Insight: BML's exit serves as a reminder that disciplined portfolio decisions can be impacted by fast-moving market catalysts, as Alumis's subsequent financing activities alleviated capital risk and reversed market sentiment, illustrating the dynamic nature of the biotech sector.
See More
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
- Market Surge: U.S. stocks rose significantly on Monday, with the Dow Jones index gaining over 350 points, indicating strong investor confidence and potentially attracting more capital into the market.
- Peakstone Realty Trust Price Surge: Shares of Peakstone Realty Trust soared 32.5% to $20.70 on Friday, reflecting positive market sentiment regarding the company's future prospects and the anticipated benefits of the acquisition.
- Acquisition Announcement: Brookfield announced plans to acquire Peakstone Realty Trust in a $1.2 billion all-cash deal, which not only enhances Brookfield's asset portfolio but also signals its strategic intent to expand further in the real estate sector.
- Positive Market Reaction: Following the acquisition news, Peakstone Realty Trust's stock price surged, indicating strong investor confidence in the deal and potentially attracting additional investment into the company.
See More
Analysts Bullish on Century Communities, Target Price Set at $92
- Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
- Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
- Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
- Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.
See More
Alumis Director Srinivas Akkaraju Purchases 588,235 Shares for ~$10 Million
- Large Transaction: On January 9, 2026, Srinivas Akkaraju purchased 588,235 shares of Alumis at $17 per share for a total of approximately $10 million, marking one of the largest trades in his history and exceeding the historical median trade size by nearly 47%.
- Increased Indirect Holdings: Following this transaction, Akkaraju's indirect holdings rose to 1,853,488 shares, reflecting his confidence in Alumis's future growth, particularly as the company's stock has surged over 400% in the past year.
- Market Price Comparison: The acquisition price was below the market open of $18.50 and close of $19.56 on January 9, 2026, indicating a favorable entry point for Akkaraju ahead of subsequent price increases, suggesting expectations of further appreciation.
- Clinical Trial Success: Alumis recently reported that 65% of patients in two Phase 3 trials with envudeucitinib achieved a 90% or better improvement in their psoriasis area and severity index (PASI) scores, indicating superior efficacy compared to Amgen's Otezla, further boosting market confidence in its products.
See More
Alumis (NASDAQ:ALMS) Acquires 588,235 Shares for $10 Million
- Share Acquisition: On January 9, 2026, Alumis Director Srinivas Akkaraju purchased 588,235 shares at $17 each for a total of approximately $10 million, demonstrating strong confidence in the company's future growth prospects.
- Holding Proportion Change: This transaction increased Akkaraju's indirect holdings to 46.49%, with no direct holdings reported post-transaction, indicating a strategic investment approach through the Samsara Opportunity Fund, L.P.
- Stock Performance: Alumis's stock has appreciated by 206.29% over the past year and surged over 400% in the last three months, reflecting strong market recognition and potential for its biotechnology products.
- Clinical Trial Success: Recent Phase 3 trial results from Alumis revealed that 65% of patients using envudeucitinib achieved a 90% or better improvement in their Psoriasis Area and Severity Index (PASI) scores, indicating its potential to outperform competitor Otezla in treating psoriasis.
See More
Activist Investors Target Staar Surgical, Alumis, and Other Stocks
Increased Investments: There has been a notable rise in holdings across various sectors, indicating a growing confidence among investors.
Market Trends: The increase in holdings reflects broader market trends, suggesting potential growth opportunities in the near future.
See More
